Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
about
Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemiaCancer as an evolutionary and ecological processABL tyrosine kinases: evolution of function, regulation, and specificityMED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signalingAllosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patientsEGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinibFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaMUC1-C Oncoprotein Blocks Terminal Differentiation of Chronic Myelogenous Leukemia Cells by a ROS-Mediated MechanismClinical use of crizotinib for the treatment of non-small cell lung cancerAMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLSelectivity and therapeutic inhibition of kinases: to be or not to be?Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndromeCombined surgical and molecular therapy: the gastrointestinal stromal tumor modelSequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainEGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly headTwo different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case reportA screen to identify drug resistant variants to target-directed anti-cancer agentsCancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesNew Developments in Chronic Myeloid Leukemia: Implications for TherapyChronic myeloid leukemia: reminiscences and dreamsTo wake up cancer stem cells, or to let them sleep, that is the questionThe Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsManagement of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentDifferent Facets of Copy Number Changes: Permanent, Transient, and AdaptiveHsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaEfficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature ReviewEvolutionary determinants of cancerClinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challengesNetwork-based approaches in drug discovery and early developmentMolecular mechanisms for survival regulation of chronic myeloid leukemia stem cellsTen things you should know about protein kinases: IUPHAR Review 14Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsTargeting JAK2 in the therapy of myeloproliferative neoplasmsMnk kinase pathway: Cellular functions and biological outcomesTargeting cancer with kinase inhibitorsTumour heterogeneity and the evolution of polyclonal drug resistanceResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsIn vitro selection of mutant HDM2 resistant to Nutlin inhibition
P2860
Q21245701-71EC27FD-4155-4ED6-9F77-21B7E3DF7AE9Q22122026-663302AA-E53E-41E1-93E9-DD591CC2BEFBQ24299738-6142FE2A-AB3E-4C67-8224-6681C999DEE2Q24304423-1B6E28BB-4AB1-46AB-B1D5-406957CE36A5Q24321968-8A395D97-0FFE-4E0D-BD72-DC6412197D7AQ24561669-DC1ED53C-18AD-4755-B0C6-06BC4195E80DQ24561953-A6948AC7-F905-4598-B798-4EDFD0B71178Q24605527-E5F8E074-FF17-4450-9A13-9F0558739E64Q24626837-7A3DDC7F-BA71-4812-B1A2-4E8D721529D5Q24630466-93ECBF50-015E-4533-99F2-59FD69C63A2CQ24651465-C297230C-5FEB-4913-8B7B-B489292B453CQ24656006-E5C3642B-0642-496A-8C5B-BAAC3588EF3BQ24670121-FA04DAE0-BC8D-4D67-BFCD-6D5A1B68CB28Q24675987-195547A2-C971-41C9-975E-8CEAEBD694ABQ24681743-AA39B061-5573-432E-B400-217EC6853A02Q24794765-02D66D2C-6075-4B5D-97C3-32047EB41C41Q24794815-7C3298D2-1D93-4F88-BA2B-DDD74E8CA80DQ24800045-4802C048-F679-446D-BC47-54CBD3D28ECEQ24806543-8EF41C6A-61F2-4F09-8F21-FB4881A94D02Q26741009-8A19924E-D607-4844-96A5-7598F6BD6174Q26745669-C46F3F80-8351-493C-80AE-15BAB581A95BQ26748769-CFE172BA-F5E6-439F-A188-2C970C7C4635Q26749632-F4E087EB-319F-4F1C-824A-BA3100BE6309Q26765247-80512432-E37C-4B54-824C-06CBCC9F761AQ26766299-45B9CCBB-5964-428E-B3CB-A434019E97ECQ26769649-822162EA-411E-41F7-A828-DF11E5EC574EQ26771790-E470ED8C-8AB2-4DB4-9A70-C6C8A72EAB0DQ26775622-E6F63853-2D24-4791-9BB5-F68453D18B6AQ26801710-E856CF60-027B-4227-A968-0987F5E2C2FFQ26823978-FBC82B74-E255-4D85-BF6D-C9B0DD0BCBF4Q26827940-FC612996-4E5A-4694-BAE2-159BB7C91431Q26828528-0F67AEB7-9CF3-45C3-9236-DFBED919C817Q26849417-0CC1E56A-A39D-4DFD-9DE1-50FDF3BC6DEFQ26849792-5C42AF39-5E70-4812-A702-65AAA333AF1EQ26860796-E07BD09C-F7C2-422B-858E-9D8751E6976CQ26865459-7E646B8E-748B-42F0-AD4C-5AFB27023209Q26865765-557CC7E6-7852-4576-A0C8-33AA36984FD3Q26866803-D3D484ED-EBC5-43C7-BADD-450E83131839Q27028181-609DBB7E-DD34-48FF-9C32-4AC2678806A2Q27322456-6A6A8E2F-E35A-449D-96D3-62AA7692E46E
P2860
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical resistance to STI-571 ...... gene mutation or amplification
@ast
Clinical resistance to STI-571 ...... gene mutation or amplification
@en
type
label
Clinical resistance to STI-571 ...... gene mutation or amplification
@ast
Clinical resistance to STI-571 ...... gene mutation or amplification
@en
prefLabel
Clinical resistance to STI-571 ...... gene mutation or amplification
@ast
Clinical resistance to STI-571 ...... gene mutation or amplification
@en
P2093
P3181
P356
P1433
P1476
Clinical resistance to STI-571 ...... gene mutation or amplification
@en
P2093
Mohammed M
Paquette R
Sawyers CL
P304
P3181
P356
10.1126/SCIENCE.1062538
P407
P577
2001-08-03T00:00:00Z